5th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals
25th — 27th February 2013
Munich, Germany
Downloads
Tuesday, February 26th, 2013
Micro-Flow Imaging and resonant mass measurements (Archimedes) evaluated for a quantitative differentiation of protein particles and silicone oil droplets Andrea Hawe (Coriolis Pharma)
Neutralizing anti-drug antibodies: Emerging Trends and Clinical Impact Arno Kromminga (IPM Biotech)
When big is not beautiful; Aggregation minimisation and characterisation of biopharmaceuticals from discovery to commercial Phase Clemens Stilling (UCB Pharma)
Binding Antibodies: Assay Methodologies, Screening Confirmation, Characterization of Anti-Drug-Antibodies Daniel Kramer (Merck Serono)
Multiple Sclerosis: Immunogenic potential of interferon-beta and physicochemical properties of anti-drug antibodies Florian Deisenhammer (Innsbruck Medical University)
Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk “Goals and Update” Marc Pallardy (INSERM) & Dan Sikkema (GSK)
Immune mechanisms underlying immunogenicity of therapeutic proteins in immune tolerant mice Grzegorz Kijanka (University of Utrecht)
Wednesday, February 27th, 2013
Harmonization of Clinical Immunogenicity Reporting... An AAPS Initiative Gopi Shankar (Janssen)
Effects of Silicone-Water Interfaces on Protein Structure, Aggregation, Particle Formation and Immunogenicity John F. Carpenter (University of Colorado)
Working towards building a “Value Added Proposition” for Immunogenicity Prediction and Risk Management Manoj Rajadhyaksha (Regeneron Pharmaceuticals)
A novel flow cytometry based technology for the quantification and characterization of sub-visible particles in protein therapeutics Mantas Malisauskas (Baxter)
Pitfalls in the Establishment of Cut Points for ADA Assays Using the ECL Method Michael Schaab (University of Leipzig)
Mastering Immunity ProPresent® Antigen Presentation Assay Nikolai Schwabe (ProImmune)
High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays Soren Buus (University of Copenhagen)
ADA to ada: Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies Theo Rispens (Sanquin)
Glycosylation as cause of drug hypersensitivity against protein drugs Uta Jappe (Research Center Borstel)
Current Experience in Immunogenicity Assessment of next Generation Biologics Nanobodies® Veerle Snoeck (Ablynx)
Drug allergy is no allergy Werner J. Pichler
Protein Aggregates and Subvisible Particles: What are they and what is their clinical impact? Wim Jiskoot (Leiden Academic Centre for Drug Research (LACDR))
